Novo Nordisk shares tumble 18% after 2026 sales dip warning
Novo blamed US pricing erosion and patent expiries in several markets for the bleak 2026 outlook.
Novo blamed US pricing erosion and patent expiries in several markets for the bleak 2026 outlook.
The partnership is the latest in a long line of AI-centric projects in drug discovery and development.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Huawei’s three key steps to drive industrial intelligence forward and unleash AI’s full potential
First responders see AI and other advanced tech as essential
What does the EU Data Act mean for businesses?
Trump blames Covid-19 drugmakers for fuelling CDC turmoil